TrialAdvances in therapy2023

Efficacy, Safety, Patient Experience, and Tolerability of Risankizumab Administered by On-Body Injector for Moderate to Severe Crohn's Disease.

Edward V Loftus et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.